ストックスクリーナーアプリを入手
1.32
2.94%
-0.04
アフターアワーズ：
1.31
-0.01
-0.76%
MAIA Biotechnology Inc (MAIA) 最新ニュース
MAIA Biotechnology Holds Steady at $1.30, Consolidating Between Support and ResistanceETF Creation Redemption - newsline.com
MAIA Biotechnology (MAIA) Holds Steady at $1.30 as Consolidation Phase EmergesStock News - newsline.com
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial - Yahoo Finance
MAIA Q1 2026 Earnings: EPS Beat on Lower Net Loss, Focus on Clinical PipelineConsensus Beat Rate - newsline.com
MAIA Biotechnology Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEPS Consistency Score - newsline.com
MAIA Biotechnology Inc. (MAIA) announced that its pivotal Phase III clinical trial for non-small cell lung cancer is showing strong momentum in patient enrollment and dosing. - Bitget
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial - The Manila Times
MAIA Biotechnology Reports Patient Enrollment Progress in Phase 3 Trial of Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer - Quiver Quantitative
Lung cancer trial drug saw 17.8-month survival vs 5.8 on chemo in MAIA study - Stock Titan
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion - The Manila Times
FDA clears U.S. trial of MAIA lung cancer drug for third-line patients - Stock Titan
Top MAIA Biotechnology Insiders Make Bold Moves With Fresh Stock Purchases - TipRanks
Maia Biotechnology CSO Sergei Gryaznov buys $2,690 in common stock By Investing.com - Investing.com Canada
MAIA Biotechnology Announces Open Market Purchases by CEO and Director - The Manila Times
MAIA Biotechnology Executives Increase Stock Holdings, Express Confidence in Cancer Immunotherapy Development - Quiver Quantitative
Maia Biotechnology director Stan Smith buys $100,200 in company stock By Investing.com - Investing.com Australia
Maia Biotechnology CEO Vlad Vitoc buys $100,885 in company stock - Investing.com UK
Maia Biotechnology CSO Sergei Gryaznov buys $2,690 in common stock - Investing.com
Maia Biotechnology director Stan Smith buys $100,200 in company stock - Investing.com
Maia Biotechnology CEO Vlad Vitoc buys $100,885 in company stock By Investing.com - Investing.com India
MAIA Biotechnology (MAIA) CEO Vitoc Vlad adds 72,700 shares in open-market buy - Stock Titan
Director Stan Smith adds 75,000 MAIA (NASDAQ: MAIA) shares via trust purchase - Stock Titan
MAIA (MAIA) Chief Scientific Officer purchases 2,000 company shares in market trade - Stock Titan
MAIA (MAIA) CEO awarded 800,000 stock options at $1.39 exercise price - Stock Titan
MAIA Biotechnology (MAIA) grants CSO 400,000 stock options at $1.39 - Stock Titan
MAIA Biotechnology (MAIA) grants 60,000 stock options to head of finance - Stock Titan
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology - The Manila Times
MAIA Biotechnology presents Phase 3 trial design for novel lung cancer drug at ASCO 2026 - Pluang
MAIA Biotechnology Inc. (MAIA) Surges 7.75%: Potential Breakout Above Key Resistance?Institutional Buy Signals - The Legal Advocate
MAIA Biotechnology Inc. (MAIA) Gains 3.91% as Biotech Momentum Lifts Shares from Support LevelsBreakaway Gap - thelegaladvocate.com
MAIA Biotechnology Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Continued Pipeline ProgressProfit Guidance Range - The Legal Advocate
MAIA Biotechnology, Inc. 8-K Filing: Annual Meeting Results, Company Details, and NYSE American Listing - Minichart
Maia Biotechnology shareholders re-elect directors and ratify auditor at annual meeting By Investing.com - Investing.com South Africa
Maia Biotechnology shareholders re-elect directors and ratify auditor at annual meeting - Investing.com Australia
MAIA Biotechnology Shareholders Back Board and Auditor Appointments - TipRanks
MAIA Biotechnology (MAIA) investors back 2026 directors and auditor at meeting - Stock Titan
MAIA Biotechnology (MAIA) Q1 2026 Earnings Surprise: EPS $-0.14, Up SignificantEarnings Expansion Phase - newsline.com
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - Yahoo Finance
MAIA Biotechnology (MAIA) Flat at $1.26 — Consolidation Continues 2026-05-18Beta Signals - newser.com
MAIA (NASDAQ: MAIA) Solas Capital and F. T. Golden report 7.1% ownership - Stock Titan
MAIA Biotechnology Ends ATM Stock Offering Agreement - TipRanks
Maia BiotechnologyTo Terminate At The Market Offering Agreement Effective May 23, 2026SEC Filing - TradingView
MAIA Biotechnology (MAIA) halts ATM share sales and terminates program - Stock Titan
MAIA (NYSE American) terminates ATM with H.C. Wainwright after $5.68M raised - Stock Titan
TradingKey - TradingKey
MAIA Biotechnology (NYSEAMERICAN:MAIA) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
MAIA Biotechnology (MAIA) delivers Q4 earnings beat, cutting losses by 32% as clinical pipeline advances.Market Expert Watchlist - Newser
MAIA Biotechnology, Inc. 1Q 2026: Net income $(6.37M), EPS $(0.14) — 10-Q Summary - TradingView
MAIA Biotechnology (MAIA) boosts cash with $33M raise as NSCLC trials advance - Stock Titan
MAIA Biotechnology | 424B5: Prospectus - Moomoo
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Rises By 23.0% - MarketBeat
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):